Prognostic Value of Biomarkers in RCC

Video

Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Related Content
Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.

FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset

Tim Cortese
October 22nd 2025
Article

Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Radioligand Therapy Combo Boosts rPFS in PSMA+ Metastatic HSPC

Chris Ryan
October 19th 2025
Article

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Bladder cancer

Disitamab Vedotin/Toripalimab Combo Prolongs Survival in Frontline HER2+ Urothelial Cancer

Tim Cortese
October 19th 2025
Article

Disitamab vedotin plus toripalimab achieved a median 13.1-month PFS and median 31.5-month OS in patients with HER2-expressing advanced urothelial carcinoma.

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.

Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer

Tony Berberabe, MPH
October 19th 2025
Article

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.